Company: BIVIW
Filing Date: 2025-08-04
Form Type: S-1/A
Source: 0001520138-25-000235
Chunk: 142

Company: BIOVIE INC.
Filing Date: 2025-08-04
Form: S-1/A
Chunk 142
---
) fees and expenses of the transfer agent
for the securities; (i) stock transfer and/or stamp taxes, if any, payable upon the transfer of securities from the Company to the Representative;
(j) the fees and expenses of the Company’s accountants; (k) the fees and expenses of the Company’s legal counsel and other
agents and representatives; (l) the fees and expenses of the underwriters’ legal counsel not to exceed $75,000; (m) the $15,000
cost associated with the use of Ipreo’s book building, prospectus tracking and compliance software for this offering; and (n) up
to $7,500 of the Representative’s market making and trading, and clearing firm settlement expenses for this offering. Such reimbursement
shall be paid at each closing (to the extent not paid at a prior closing) from the gross proceeds of the Securities.

The Representative may also ask other FINRA member
broker-dealers that are registered with the SEC to participate as soliciting dealers for this offering.

We have paid an expense deposit of $50,000 to
the Representative, which will be applied against the out-of-pocket accountable expenses that will be paid by us to the underwriters in
connection with this offering and will be reimbursed to us to the extent not actually incurred in compliance with FINRA Rule 5110(g)(4)(A).

Our total estimated expenses of the offering,
including registration, filing and listing fees, printing fees and legal and accounting expenses, but excluding underwriting discounts
and commissions and excluding the non-accountable expense allowance, are approximately $450,000.

Representative’s Warrants

Upon closing of this offering, we have agreed
to issue the Representative warrants (“Representative’s Warrants”) to purchase up to 5% of the aggregate number of
Units and Pre-funded Units sold. The Representative’s Warrants will be exercisable at an exercise price of $9.4375 (representing
125% of the assumed public offering price of $7.55 per Unit, the last reported sale price of our Common Stock as reported on Nasdaq
on July 24, 2025). The Representative’s Warrants are immediately exercisable and will expire on the four- and one-half year
anniversary of the date that is 180 days from the commencement of sales of the securities issued in this offering.

<div align='center'>79</div>

The Representative’s Warrants have been
deemed compensation by FINRA and are therefore